NASDAQ:NTLA

Intellia Therapeutics - NTLA News Today

$39.79

+1.52 (+3.97%)

(As of 03/21/2023 12:00 AM ET)

Add

Compare

Today's Range: $38.25
▼
$39.94
50-Day Range: $33.30
▼
$44.82
52-Week Range: $32.44
▼
$78.58

Volume: 1.02 million shs
Average Volume: 1.20 million shs
Market Capitalization: $3.50 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $89.25

Institutional Ownership

Get Intellia Therapeutics News Delivered to You Automatically

NTLA Media Mentions By Week

NTLA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NTLA
News Sentiment
▼
0.79

0.34
▲
Average
Medical
News Sentiment

NTLA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NTLA Articles
This Week
▼
8

3
▲
NTLA Articles
Average Week

Source

Source	Headline
	Intellia Therapeutics (NASDAQ:NTLA) Coverage Initiated by Analysts at Sanford C. Bernstein marketbeat.com - March 21 at 7:33 AM
	McGuire Investment Group LLC Purchases New Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) marketbeat.com - March 17 at 10:57 AM
	McGuire Investment Group LLC Acquires New Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) marketbeat.com - March 17 at 10:57 AM
	3 More Mid-Cap Biotechs The Street Sees Doubling marketbeat.com - February 22 at 8:45 AM
	Intellia Therapeutics Gets FDA RMAT Designation for NTLA-2002 in Hereditary Angioedema marketwatch.com - March 21 at 12:50 PM
	Intellia Therapeutics Stock (NASDAQ:NTLA), Short Interest Report benzinga.com - March 17 at 8:10 PM
	BMO Capital Upgrades Intellia Therapeutics (NTLA) msn.com - March 15 at 8:41 PM
	Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Outperform at BMO Capital Markets americanbankingnews.com - March 15 at 1:24 AM
	Analysts Offer Insights on Healthcare Companies: Durect (DRRX) and Intellia Therapeutics (NTLA) markets.businessinsider.com - March 13 at 6:28 PM
	“Strong Buy” Intellia Therapeutics Stock (NASDAQ:NTLA) Still Requires Prudence markets.businessinsider.com - March 8 at 2:01 AM
	Intellia Therapeutics Climbs 7% On Clearance Of NDA For NTLA-2002 nasdaq.com - March 4 at 11:10 PM
	BMO Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA) markets.businessinsider.com - March 3 at 11:56 AM
	Intellia Gets FDA Nod to Start Testing Crispr Therapy bloomberg.com - March 2 at 4:30 PM
	Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today? markets.businessinsider.com - March 2 at 4:30 PM
	Why Intellia Therapeutics Stock Jumped This Week msn.com - March 2 at 4:30 PM
	Intellia stock rises on FDA nod to start trial of CRISPR gene editing therapy msn.com - March 2 at 11:30 AM
	Intellia shares jump as gene therapy trial gets U.S. regulator nod reuters.com - March 2 at 11:30 AM
	Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing finance.yahoo.com - March 2 at 11:30 AM
	Intellia Therapeutics Earnings Perspective: Return On Capital Employed msn.com - February 28 at 2:14 PM
	Intellia Therapeutics, Inc. (NTLA) Q4 2022 Earnings Call Transcript seekingalpha.com - February 26 at 12:26 AM
	Intellia Therapeutics GAAP EPS of -$1.40 misses by $0.04, revenue of $13.6M beats by $2.89M msn.com - February 23 at 9:03 AM
	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress finance.yahoo.com - February 23 at 9:03 AM
	Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year? finance.yahoo.com - February 22 at 12:59 PM
	Better Buy: Beam Therapeutics or Intellia Therapeutics? finance.yahoo.com - February 22 at 6:11 AM
	$14.2+ Billion Worldwide Gene Editing Industry to 2032 - Rising Infectious Diseases Drives Growth benzinga.com - February 16 at 8:26 PM
	Intellia Therapeutics Stock (NASDAQ:NTLA), Quotes and News Summary benzinga.com - February 14 at 3:12 PM
	Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to Trade finance.yahoo.com - February 6 at 1:43 PM
	Does Intellia Therapeutics Stock Have Good Genes? finance.yahoo.com - February 1 at 9:23 AM
	BlackRock Inc. Increases Position in Intellia Therapeutics Inc (NTLA) nasdaq.com - January 27 at 3:33 PM
	ZM, NTLA, or SQ: Which Cathie Wood’s ARKK ETF Stock Seems More Appealing in 2023? markets.businessinsider.com - January 7 at 7:37 AM
	Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones finance.yahoo.com - January 5 at 9:49 AM
	Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month? forbes.com - December 19 at 8:37 AM
	Verve drops 21% as FDA seeks more data to lift clinical hold on lead asset seekingalpha.com - December 5 at 5:59 PM
	Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Pricing of Public Offering of Common Stock finanznachrichten.de - December 1 at 5:51 AM
	Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94% markets.businessinsider.com - November 15 at 8:50 AM
	Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates finance.yahoo.com - November 14 at 9:27 AM
	Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting finance.yahoo.com - November 12 at 9:46 PM
	Verve Therapeutics Crushed By Clinical Hold thestreet.com - November 7 at 9:20 PM
	SVB Securities Keeps Their Buy Rating on Intellia Therapeutics (NTLA) markets.businessinsider.com - November 7 at 12:17 AM
	Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y nasdaq.com - November 4 at 2:18 PM
	Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y finance.yahoo.com - November 3 at 4:44 PM
	Earnings Preview For Intellia Therapeutics msn.com - November 2 at 4:17 PM
	Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance finance.yahoo.com - November 2 at 4:17 PM
	Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates technews.tmcnet.com - October 27 at 7:32 PM
	10 Best Gene Editing Stocks To Buy finance.yahoo.com - October 14 at 10:26 AM
	Intellia Therapeutics Inc (38I) uk.investing.com - October 11 at 8:35 PM
	Intellia Therapeutics Inc Shares Close the Day 10.6% Lower - Daily Wrap nasdaq.com - October 8 at 9:48 AM
	‘Take Opportunities on Days Like Today’: Mary Callahan Erdoes Says Now Could Be the Best Time to Invest. Here Are 3 Stocks to Consider finance.yahoo.com - October 7 at 12:49 AM
	Cathie Wood Is Loading Up on These 3 Stocks: Should You? finance.yahoo.com - September 20 at 5:03 PM
	Intellia Therapeutics Falls 14% Despite Positive Phase 1 Results nasdaq.com - September 16 at 3:54 PM
	Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies finance.yahoo.com - September 16 at 3:54 PM
	Intellia, Other CRISPR Stocks Hammered On Safety Concerns In New Gene-Editing Test finance.yahoo.com - September 16 at 3:54 PM
	Intellia Reports Positive Interim Data For NTLA-2002 In Treatment Of Hereditary Angioedema nasdaq.com - September 16 at 10:52 AM
	Intellia gains after positing early data for gene-edited hereditary angioedema candidate seekingalpha.com - September 16 at 10:52 AM

Get Intellia Therapeutics News Delivered to You Automatically

This page (NASDAQ:NTLA) was last updated on 3/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intellia Therapeutics - NTLA News Today

NTLA Media Mentions By Week

NTLA Media Sentiment

NTLA News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info